Comparative Pharmacology
Head-to-head clinical analysis: INVEGA TRINZA versus LUMATEPERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVEGA TRINZA versus LUMATEPERONE.
INVEGA TRINZA vs LUMATEPERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic that antagonizes central dopamine type 2 (D2) and serotonin type 2 (5-HT2A) receptors. It also antagonizes alpha-1 and alpha-2 adrenergic, and histamine H1 receptors.
Lumateperone is an atypical antipsychotic with a unique mechanism of action: it acts as a 5-HT2A receptor antagonist, a dopamine D2 receptor antagonist, and a serotonin reuptake inhibitor. It also modulates glutamate via enhanced AMPA and NMDA receptor activity.
Administered intramuscularly (gluteal or deltoid) at 3-month intervals. Starting dose: 350 mg, 525 mg, or 700 mg based on prior stabilization dose of oral paliperidone or INVEGA SUSTENNA. Maximum dose: 700 mg.
42 mg orally once daily, taken with food and at least 240 mL of water, with a titration schedule: 42 mg daily for 7 days, then 21 mg twice daily thereafter.
None Documented
None Documented
Terminal elimination half-life: 3 to 6 months (mean 118 days) due to slow dissolution from intramuscular depot; clinical context: steady state reached after 3 injections every 3 months.
Terminal elimination half-life is approximately 13 hours in the plasma, supporting once-daily dosing. Steady state is reached within 5–7 days.
Renal: 59-80% as unchanged drug and metabolites; fecal: 6-15%; biliary: minimal.
Approximately 80% of the dose is excreted in feces (as unchanged drug and metabolites) and about 11% in urine. Less than 1% is excreted as unchanged lumateperone in urine.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic